Sangamo Therapeutics, Inc.
Engineered target specific nucleases

Last updated:

Abstract:

Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.

Status:
Grant
Type:

Utility

Filling date:

8 Feb 2019

Issue date:

2 Aug 2022